Biomarin Pharmaceutical Inc (BMRN) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Biomarin Pharmaceutical Inc stock (BMRN) is currently trading at $55.59. Biomarin Pharmaceutical Inc PE ratio is 30.05. Biomarin Pharmaceutical Inc PS ratio (Price-to-Sales) is 3.23. Analyst consensus price target for BMRN is $88.87. WallStSmart rates BMRN as Moderate Buy.
- BMRN PE ratio analysis and historical PE chart
- BMRN PS ratio (Price-to-Sales) history and trend
- BMRN intrinsic value — DCF, Graham Number, EPV models
- BMRN stock price prediction 2025 2026 2027 2028 2029 2030
- BMRN fair value vs current price
- BMRN insider transactions and insider buying
- Is BMRN undervalued or overvalued?
- Biomarin Pharmaceutical Inc financial analysis — revenue, earnings, cash flow
- BMRN Piotroski F-Score and Altman Z-Score
- BMRN analyst price target and Smart Rating
Biomarin Pharmaceutical Inc
📊 No data available
Try selecting a different time range
BMRN Intrinsic Value Analysis for Value Investors
Benjamin Graham Formula · Biomarin Pharmaceutical Inc (BMRN)
BMRN appears undervalued based on the Graham Formula, trading 28% below its estimated fair value of $84.24.
Based on Benjamin Graham Formula. Growth rate capped at 25%. For informational purposes only. Not financial advice.
Smart Analysis
Biomarin Pharmaceutical Inc (BMRN) · 10 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in market cap, peg ratio, operating margin. Concerns around return on equity. Overall metrics suggest strong investment potential with favorable risk/reward.
Biomarin Pharmaceutical Inc (BMRN) Key Strengths (6)
Growing significantly faster than its price suggests
Earnings per share surging 124.30% year-over-year
101.15% of shares held by major funds and institutions
Large-cap company with substantial market presence
Strong operational efficiency: $23 kept per $100 revenue
Trading at 1.71x book value, attractively priced
Supporting Valuation Data
Biomarin Pharmaceutical Inc (BMRN) Areas to Watch (4)
Low profitability relative to shareholder equity
Revenue is fairly priced at 3.23x sales
Solid revenue growth at 17.00% per year
Decent profitability, keeps $11 per $100 revenue
Supporting Valuation Data
Biomarin Pharmaceutical Inc (BMRN) Detailed Analysis Report
Overall Assessment
This company scores 75/100 in our Smart Analysis, earning a B grade. Out of 10 metrics analyzed, 6 register as strengths (avg 9.2/10) while 4 fall into concern territory (avg 5.3/10). All four categories (Growth, Profitability, Valuation, and Quality) show healthy scores, indicating broadly sound fundamentals.
The Bull Case
The strongest argument centers on PEG Ratio, EPS Growth, Institutional Own.. Valuation metrics including PEG Ratio (0.63), Price/Book (1.71) suggest the stock is attractively priced. Profitability is solid with Operating Margin at 22.50%. Growth metrics are encouraging with EPS Growth at 124.30%.
The Bear Case
The primary concerns are Return on Equity, Price/Sales, Revenue Growth. Some valuation metrics including Price/Sales (3.23) suggest expensive pricing. Growth concerns include Revenue Growth at 17.00%, which may limit upside. Profitability pressure is visible in Return on Equity at 5.94%, Profit Margin at 10.80%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Return on Equity improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at 5.94% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at 17.00% needing to reaccelerate.
Risk Considerations
Based on the metric profile, this is a moderate risk investment. The weight of evidence leans positive, with more strengths than concerns. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
The combination of PEG Ratio and EPS Growth makes a compelling case at current levels. The key risk is Return on Equity, but the overall fundamental picture is positive with a clear path to maintaining or improving the current B grade.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
BMRN Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
BMRN's Price-to-Sales ratio of 3.23x trades at a deep discount to its historical average of 13.8x (0th percentile). The current valuation is 91% below its historical high of 34.68x set in Dec 2007, and 0% above its historical low of 3.23x in Mar 2026. Over the past 12 months, the PS ratio has compressed from ~3.7x as trailing revenue scaled faster than the stock price.
WallStSmart Analysis Synopsis
Data-driven financial summary for Biomarin Pharmaceutical Inc (BMRN) · HEALTHCARE › BIOTECHNOLOGY
The Big Picture
Biomarin Pharmaceutical Inc is a strong growth company balancing expansion with improving profitability. Revenue reached 3.2B with 17% growth year-over-year. Profit margins of 10.8% are healthy, with room for further expansion as the business scales.
Key Findings
ROE of 594.0% means the company generates strong returns on shareholder equity. Above 20% is considered top-tier.
Generating 59M in free cash flow and 100M in operating cash flow. Earnings are translating into actual cash generation.
What to Watch Next
Margin expansion: can Biomarin Pharmaceutical Inc push profit margins above 15% as the business scales?
Sector dynamics: monitor BIOTECHNOLOGY industry trends, competitive moves, and regulatory changes that could impact Biomarin Pharmaceutical Inc.
Bottom Line
Biomarin Pharmaceutical Inc offers an attractive blend of growth (17% revenue expansion) and improving fundamentals. The company is transitioning from pure growth to profitable growth, a critical inflection point. Watch for sustained margin expansion as the key signal.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Loading insider activity...
About Biomarin Pharmaceutical Inc(BMRN)
NASDAQ
HEALTHCARE
BIOTECHNOLOGY
USA
BioMarin Pharmaceutical Inc. develops and markets therapies for people with rare diseases and serious and life-threatening medical conditions. The company is headquartered in San Rafael, California.